As athlete, Matthew Rybicki, finishes his journey to run 14 marathons in 14 days across the length of Poland in support of ADI, we would like to take a moment to spotlight his incredible efforts during #WorldAlzMonth. During his fundraising campaign, Matthew has raised over $4,000 for ADI – money that will have a direct impact on ADI’s work in advocating for people living with dementia globally. If you would like to follow along with and see Matthew’s journey in its entirety from the mountains at Zakopane to the Baltic coast finish line in Gdańsk, you can see more at @bymateuszz on Instagram and TikTok. If you would like to donate in support of Matthew’s run, please visit runacrosspoland.com/ Please join us in congratulating Matthew on this show of determination, of physical and mental strength, and join us as we express our deep gratitude for his efforts to raise awareness to dementia and Alzheimer’s disease.

Did you know there is more than one kind of dementia? This World Alzheimer’s Month we are issuing a global call to ask about dementia. By asking questions and learning more, we can break down stigma, encourage earlier recognition and support families everywhere. Here are some of the most common types of dementia: 🔴 Alzheimer’s disease is the most common type of dementia, accounting for up to three quarters of all cases. It is associated with abnormal protein build-ups, such as beta-amyloid plaques and tau tangles, in the brain that contribute to damage to nerve cells and affect memory, speech and decision-making. 🔴 Vascular dementia is the second most common type. It develops when blood flow to the brain is blocked or reduced, often after a series of mini strokes. Over time this can lead to confusion and difficulties with concentration. 🔴 Dementia with Lewy bodies accounts for around one in ten cases of dementia. It is associated with abnormal protein deposits in brain cells and can lead to vivid hallucinations, sleep disturbances and changes in movement alongside cognitive decline. It takes its name from abnormal accumulations of the alpha-synuclein protein in the brain, known as Lewy bodies. 🔴 Fronto-temporal dementia is rarer but often develops earlier in life. It affects the frontal lobe of the brain and is marked by changes in personality, mood and behaviour, while memory may remain intact in the early stages. This month let us ask more questions about dementia and bring greater awareness of its different forms to communities all around the world. Learn more about the types of dementia on the ADI website: alzint.org/about/dementia-fa… The earlier you know, the more you can do. A dementia diagnosis matters. #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters #EarlyDiagnosisMatters

The number of people living with dementia is expected to rise sharply in the coming decades. By 2030, an estimated 78 million people will be living with dementia globally. By 2050, that number is projected to reach 139 million. Behind the forecasted numbers are millions of people, families and communities whose lives will be affected. As the number of people living with dementia grows, ensuring earlier access to diagnosis will become increasingly important. A diagnosis can help people understand their cognitive changes, access treatment, care and support, and make decisions about the future. We need health and care systems that are ready to recognise dementia as a major health challenge, and support people up to the point of diagnosis and beyond. The earlier you know, the more you can do. A dementia diagnosis matters. #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters #EarlyDiagnosisMatter

Costa Rica, the first country in Latin America to adopt a National Dementia Plan, has taken initial steps towards reviewing and updating the plan, which came to an end in 2024. Diego Aguilar, ADI Regional Director for the Americas, joined representatives from the Ministry of Health, PAHO and ASCADA, ADI’s member association in Costa Rica, for a meeting at the PAHO offices in San José to discuss possible pathways for updating the plan. The meeting resulted in initial agreements to continue working together, recognising the importance of collaboration between government and civil society in developing and implementing an effective national response to dementia. The conversation continued through a technical roundtable convened by ASCADA, bringing together health professionals, researchers and academics to contribute evidence, experience and different perspectives on the country’s future dementia response. ADI will continue to work alongside ASCADA and national and regional partners to support Costa Rica as it moves towards the next phase of its dementia response. Learn more about ASCADA: alzint.org/member/asociacion… #WorldAlzMonth

This month, landmarks and buildings around the world will light up in purple to mark and celebrate World Alzheimer's Month. 💜 From cities and communities across the globe, these illuminations are a powerful reminder that people living with dementia, their families and carers are not alone, shining a light on this year's message: The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters. Thank you to everyone taking part and helping us raise awareness, challenge stigma and make dementia visible. Together, let's light up the world for dementia. #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters #EarlyDiagnosisMatters This photo features illuminated buildings in Buenos Aires, Dominica, Jakarta, Kolkata, Mexico City, Quito, Rio de Janeiro and Singapore.

It's World Alzheimer’s Day! Around the world, people are coming together to raise awareness of Alzheimer's disease and all types of dementia, challenge stigma and show their support for people living with dementia and their families. This year's World Alzheimer's Month campaign is focused on one important message: The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters. A diagnosis can provide answers. It can help people access treatment, care and support, make informed decisions and plan for the future. Yet too many people continue to face barriers to diagnosis, including stigma, fear, lack of awareness and unequal access to healthcare. Today we ask you to help change that. Talk about dementia. Challenge stigma. Share trusted information. Encourage people with concerns to seek advice. Together, we can help create a world where everyone can actively seek an earlier diagnosis. The earlier you know, the more you can do. Join us for our World Alzheimer's Month campaign: bit.ly/3UkBuyD Featured in this post: Alzheimer's Pakistan, Stichting Alzheimer Curaçao, Feledhetetlen, Lanka Foundation, 台灣失智症協會 Taiwan Alzheimer's Disease Association, Alzheimer Indonesia, Alzheimer Nederland, DeutscheAlzheimerGesellschaft, Alzheimer's South Africa, VI Alzheimer's Association, Alzheimer HONDURAS, Tase Fundacion, WHO, barbados alz association, Ministerio de Salud Chile, Alzheimer's Care Armenia Ալցհայմերի խնամք Հայաստան, HKADA 香港認知障礙症協會, Alzheimer's Disease Association of the Philippines, teuntoebes, Bill Gates, HKADA #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters #EarlyDiagnosisMatters

Today on World Alzheimer’s Day, ADI Regional Director for the Asia Pacific, DY Suharya was in Colombo, Sri Lanka, where the Lanka Alzheimer’s Foundation (LAF) were celebrating a momentous milestone of their 25th anniversary. Around 100 people attended the World Alzheimer’s Day and LAF anniversary celebrations including dementia advocates, the Mayor of Colombo Ms Vraie Balthazar, the co-founder of LAF Lorraine Yu, the current President of LAF Prof Shehan Williams, LAF Board Members Ms Romany Parakrama and Mrs Lakmali Cabral, and WHO Country Rep Dr Rajesh Pandav – who all came together to celebrate LAF’s milestone of 25 years of dementia care and support services for people in their country and community. As part of the festivities, DY participated in a memory walk with 200 participants on 19 September and further activities this week include a session on “training the trainers” a high-level discussion involving prominent stakeholders, a focus group discussion, in-depth interviews facilitated by experts from the region and recognition of the Lanka Alzheimer’s Foundation activity centre – which is celebrating 15 years of service for people living with dementia. The momentum is building in Sri Lanka, with all these activities and celebrations taking place with the purpose of raising awareness of dementia, but also with the goal of gathering support for a national dementia plan for Sri Lanka: a plan that can support nearing 300,000 people living with dementia in the country. #DementiaIsEverybody’sBiz #EarlyDiagnosisMatters #RoadToSriLankaDementiaPlan

The 2026 World Alzheimer Report is now available: A New Era of Dementia Clinical Trials! Dementia clinical trials are bringing new opportunities alongside important questions about how we make research more inclusive, accessible and effective to enable emerging and future innovation for dementia treatments. The 2026 World Alzheimer Report explores key issues including recruitment participation and retention, the importance of global representation, diversification and their impact on inclusive dementia research, and the need to increase awareness and understanding of clinical trials among medical practitioners. The report also explores what clinical trials are and how they work, while sharing personal perspectives and experiences from people involved in clinical research. By bringing together evidence and lived experiences, the report shines a light on recommendations to ensure the next generation of dementia clinical trials are fit to deliver global innovation for future treatments. Download the 2026 World Alzheimer Report today: bit.ly/4iF82gQ #WorldAlzReport #WorldAlzheimerReport #DementiaClinicalTrials #WorldAlzMonth

This week in Bogotá, ADI Regional Director for the Americas Diego Aguilar, alongside delegates of Alzdecolombia, Colombian researchers and academics, engaged with Senator Norma Hurtado and her team to help strengthen Colombia’s national dementia bill and support its path towards public policy, as part of the Regional Symposium on Brain Health and Dementia, organised by the Neuroscience Programme at Universidad Javeriana. ADI thanks GBHI for supporting this initiative, and Facundo Manes, Hernando Santamaría-García, Eduar Herrera and all participants for their valuable contributions. Learn more about ADI's member association for Columbia: alzint.org/member/asociacion… #WorldAlzMonth

Register for our upcoming 2026 World Alzheimer Report launch webinar, where leading experts and report contributors will explore the new era of dementia clinical trials, the human stories behind them, what participation means for a person living with dementia and what these trials could mean for the future of diagnosis, treatment and care. Register here: bit.ly/4xWzDyx Registrants will receive a download link to the report during the webinar and via email afterward, along with exclusive first access to the event recording, giving registrants the opportunity to revisit the top insights from the discussion. About the report 📌 The 2026 World Alzheimer Report explores key issues including recruitment participation and retention, the importance of global representation, diversification and their impact on inclusive dementia research, and the need to increase awareness and understanding of clinical trials among medical practitioners. The report also explores what clinical trials are and how they work, while sharing personal perspectives and experiences from people involved in clinical research. By bringing together evidence and lived experiences, the report shines a light on recommendations to ensure the next generation of dementia clinical trials are fit to deliver global innovation for future treatments. Register today and join us as we launch the 2026 edition of the World Alzheimer Report. We look forward to welcoming you.

What happens when you see a doctor about changes in your memory or thinking? A cognitive assessment may be one part of the process. Cognitive assessments can help healthcare professionals understand how someone is thinking, remembering, concentrating and solving problems. They are one of the tools that can contribute to understanding what may be causing changes in cognition. A cognitive assessment is not, on its own, a diagnosis of dementia. Healthcare professionals may consider the results alongside a person's symptoms, medical history and other assessments to understand the bigger picture. Knowing what to expect can make the process feel less daunting and may help people feel more confident about raising concerns with medical practitioners. If you have noticed some of the warning signs of dementia, don't be afraid to ask questions and seek advice. The earlier you know, the more you can do. A dementia diagnosis matters. #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters #EarlyDiagnosisMatters

The launch of the 2026 World Alzheimer Report is just a few days away! This year, the report focuses on dementia clinical trials, coming at a time when clinical trials are transforming the landscape of dementia research. Advances in biomarkers, genetic research, and trial design have contributed to the first disease-modifying treatments for Alzheimer’s and renewed optimism across the wider dementia field. Ahead of the launch, ADI is sharing another early preview into this year’s report for our global network. Chapter 3, 'Clinical trials in dementia: Complexity and opportunities,' explores the specific challenges and opportunities that arise when developing and testing new interventions for dementia. Researchers are increasingly able to identify the condition earlier, recruit more appropriate trial participants, and test interventions with greater precision than ever before. Yet dementia remains one of the most challenging areas of medicine in which to develop new therapies. The biological complexity of different forms of dementia, difficulties in diagnosis, lengthy trial timelines, high costs, and the need to recruit diverse populations all mean that progress can be slow. This chapter explores how clinical trials are evolving across both pharmacological and non-pharmacological interventions. It also examines efforts to expand research beyond traditional centres in North America and Europe, recognising that globally representative clinical trials are essential if future treatments are to benefit all populations. Crucially, the chapter asks an increasingly important question as new therapies emerge: what constitutes meaningful success in a clinical trial? For researchers, regulators, and the pharmacological industry, success may be measured through statistical significance; for people living with dementia and their loved ones, preserving independence and maintaining quality of life is often paramount. To learn more about the complexity and opportunities within dementia clinical trials, register for our World Alzheimer Report 2026 launch webinar: A new era in dementia clinical trials, taking place on 21 September 2026 at 14:00 BST. Register today! bit.ly/4xWzDyx #WorldAlzheimerReport #DementiaClinicalTrials #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters

¿Sabías que existen 10 señales de alerta comunes de la demencia? Este #WorldAlzMonth, queremos animar a nuestra red global a conocer mejor los síntomas de la demencia, para que las personas y sus familias puedan dar pasos importantes hacia un diagnóstico temprano. Si tú o alguien cercano ha notado cambios en la memoria, el pensamiento o el comportamiento, consultar con un profesional de la salud puede ser el primer paso. Aunque recibir un diagnóstico puede generar miedo, saber qué está pasando puede ayudar a comprender mejor lo que está ocurriendo, acceder a tratamiento, atención y apoyo, y tomar decisiones informadas sobre el futuro. Este Mes Mundial del Alzheimer, puedes consultar el póster de ADI “10 señales de alerta de la demencia”, diseñado para ayudar a reconocer algunos de los signos más comunes, desde problemas de memoria que interfieren con la vida cotidiana hasta dificultades para resolver problemas, comunicarse o cambios en el estado de ánimo y el comportamiento. El póster está disponible en 10 idiomas. Consulta los materiales aquí: bit.ly/Dementia-Warning-Sign… #WorldAlzMonth

Dementia is not a normal part of ageing. Yet 65% of health and care professionals incorrectly believe that dementia is a normal part of getting older. This misconception can have serious consequences. When changes in memory, thinking or behaviour are dismissed as a normal part of ageing, people may be less likely to seek medical advice and receive an earlier diagnosis. This World Alzheimer’s Month, you can access ADI’s '10 Warning Signs of Dementia' poster, designed help people recognise the most common signs, from memory loss that disrupts daily life to challenges with problem-solving, language or changes in mood and behavior. The poster is available in 10 languages. Access the posters today: bit.ly/dementia-warning-sign… Greater awareness among health and care professionals, alongside the wider public, is essential to recognising dementia and supporting people to access the right care. This World Alzheimer's Month, let's challenge misconceptions about dementia that deny a person living with dementia, their family and their carers the access to available support, whether it is through disease modifying treatments, additional care, post-diagnosis risk reduction and crucial information. The earlier you know, the more you can do. #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters

ADI is delighted to announce that Dr Faith Mwangi-Powell will join us as Chief Executive Officer on 1 October 2026. We warmly invite you to welcome Faith as she takes up her role and we begin an exciting new chapter for ADI and the global dementia community. Faith joins ADI bringing more than 25 years of diverse experience and expertise in global health and international development, including leading global and regional movements advancing health, rights and care. These include, among others, Girls Not Brides, the Global Partnership to End Child Marriage; The Girl Generation, the Africa-Led Movement to End Female Genital Mutilation (FGM); and the African Palliative Care Association. Across her career, Faith has led organisations, teams and partnerships in diverse countries and contexts, with a strong track record of developing global and regional strategies, shaping policy, mobilising resources and bringing together diverse stakeholders to drive meaningful and sustainable change. Her expertise spans health systems strengthening, palliative care, quality improvement, sexual and reproductive health, philanthropy, research and advocacy. At its heart, her work has been translating global commitments and policy into action, holding leaders and institutions accountable for their commitments, driving systemic change and working in partnership with vulnerable and underserved communities to advance the change they identify and seek. This experience brings valuable perspectives to ADI’s mission and its work to advance the rights, care and support of people living with Alzheimer’s disease and other dementias, their families and carers. Faith joins ADI at a pivotal moment for the global dementia movement. Advances in diagnosis, treatment, prevention and risk reduction are creating new opportunities and optimism, while innovation continues to outpace policy and practice. The extension of the WHO Global Action Plan on Dementia to 2031, alongside dementia’s inclusion in the UN Political Declaration on noncommunicable diseases and mental health, provides important momentum for global action.

There is just one week remaining before the launch of the 2026 World Alzheimer Report, focusing this year on dementia clinical trials. You don't need to be a neuroscientist to decipher the report! The report illuminates how clinical trials work and how they are experienced by those participating, as well as highlights the challenges to the dementia treatment pipeline. Ahead of the launch, ADI is sharing an early preview into the report for our global network. Chapter 2, 'Understanding clinical trials: How new dementia treatments are developed,' provides an accessible introduction to clinical trials and foundational explanations of how new dementia treatments are developed through the rigorous clinical trial process. Clinical trials are the foundation of modern medicine, providing the evidence needed to determine whether new treatments are safe, effective, and suitable for widespread use. Every medicine currently prescribed for Alzheimer’s disease and other forms of dementia has reached people affected by the condition only after progressing through stages of scientific testing. This chapter follows the journey of a potential medicine from laboratory discovery, through testing in cells and animals, into carefully designed studies involving people, and ultimately to regulatory approval and use in everyday clinical practice. It explains the different phases of clinical trials, why most experimental treatments fail, and why the drug development process, although slow and expensive, is critical for protecting patients and generating reliable evidence. The chapter will unpack terms such as “Phase 3,” “placebo-controlled,” and “double-blind,” explaining what they mean in the context of developing a potential dementia treatment, as well as examining what these development pipelines mean in a global context, including the complex organisational and research structures through which potential treatments are developed, tested, and brought towards clinical use. To learn more about how new dementia treatments are developed, register for our World Alzheimer Report 2026 launch webinar: A new era in dementia clinical trials, taking place on 21 September 2026 at 14:00 BST. Register today! bit.ly/4xWzDyx #WorldAlzheimerReport #DementiaClinicalTrials #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters

What are PET scans and how can they help diagnose dementia? PET stands for Positron Emission Tomography and uses a safe, injectable radioactive chemical called a ‘radiotracer’ to highlight areas in the brain. PET scans are a unique form of diagnostic imaging, because they monitor molecular activity and processes within your body, which allows for earlier detection of conditions like Alzheimer’s or dementia. Unfortunately, global access to PET scanners remains a challenge. According to the International Atomic Energy Agency, only 110 countries globally have PET scanners. Of those countries, only 26% are low or lower-middle income countries. It is therefore critical to address global inequalities in access to diagnostic methods, such as PET scanning, if we are to effectively encourage and advocate for earlier diagnosis. This September, join us as we shine a light on the importance of an early diagnosis. Take part in the campaign today! bit.ly/3UkBuyD The earlier you know, the more you can do. A dementia diagnosis matters. #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters #EarlyDiagnosisMatters

The 2026 World Alzheimer Report critically examines the new era of dementia clinical trials that we currently find ourselves in, going beyond the science to reveal the human perspectives at the heart of each and every clinical trial. Chapter 4 of the report highlights the importance of recruitment, adherence and global participation. Trials are dependent on scientific innovation to bring success, but they are also measured also on their ability to recruit, retain, and support trial participants from diverse backgrounds. As it stands, many low- and middle-income countries are underrepresented in the clinical trial space, despite being home to 60% of people living with dementia globally. This chapter also reflects on further inequities in trial participation: women, ethnic minorities, and socially disadvantaged communities are underrepresented in dementia clinical trials, affecting the reliability of trial results in the real world. Chapter 4 includes input from experts in the space, including Dr Sharon Cohen, medical director of the Toronto Memory Program in Canada; Professor Miia Kivipelto, Professor of Clinical Geriatrics at Karolinska Institutet and one of the architects of the pioneering FINGER prevention study; Professor Colin Masters, Australian neuroscientist; and many more. To learn more about the challenges and opportunities of diversity and inclusion within clinical trials, register for our World Alzheimer Report launch webinar taking place on 21 September 2026 at 14:00 BST. Register today! bit.ly/4xWzDyx #WorldAlzheimerReport #DementiaClinicalTrials #WorldAlzheimerMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters

Dementia impacts far more than the person receiving a diagnosis. It can have a profound impact on families, carers and communities too. Currently 50% of the global costs associated with dementia are related to informal care. With the overall global cost of dementia forecast to reach 2.8 trillion by 2030. Family members and friends provide millions of hours of unpaid care and support to people living with dementia. This contribution is invaluable, but it can also come with significant emotional, physical and financial pressures. The impact of informal care falls disproportionately on women, as well as in low to middle-income countries. This World Alzheimer’s Month, ADI is calling for global attention on these disparities in dementia care and costs. With an earlier diagnosis, a family or community can be given more time to think about care needs and access the right support for different stages of the condition, enabling a better quality of life, for longer. Supporting people to receive an early diagnosis is not only about the person living with dementia. It is about supporting the people around them, too. The earlier you know, the more you can do. A dementia diagnosis matters. #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters #EarlyDiagnosisMatters